Blood Transfusion in Patients With Lung Cancer

NCT05590429 | Unknown

• 1 other identifier: 24237859-782
• Study Type: observational
• Target: 400
• Locations: 1 country
• Sites: 1

Brief Summary

The main purpose of approaching the anemic patient is to provide and maintain hemoglobin levels that will allow oxygen to reach the tissue at an adequate level. This critical level may vary from patient to patient, the age of the patient and other accompanying diseases are among the determining factors. The most important factor in transfusion indication is the insufficiency of cardiopulmonary compensation mechanisms due to anemia in the patient and the patient becoming symptomatic. Red blood cell (RBC) transfusions are common in the treatment of cancer patients. In cancer patients, similar to other patient populations, the indication for RBC transfusion is to alleviate anemia, which is actually symptomatic. However, the decision to transfuse should not be guided solely by the hemoglobin concentration. With this study, it is aimed to develop clinical practices to prevent unnecessary transfusion practices in lung cancer patients, to encourage the application of other supportive treatment options, and to take preventive measures before anemia develops

Conditions

Transfusion-Transmitted Infection

Keywords

Hemoglobin, lung canser, complication

Outcome Measures

Primary Outcomes (1)

• evaluate the relationship between blood transfusion frequency and disease prognosis

  With this study, it is aimed to develop clinical practices to prevent unnecessary transfusion practices in lung cancer patients, to encourage the application of other supportive treatment options and to take preventive measures before anemia develops.

  01.10.2020-01.06.2022

Interventions

Blood transfusion OTHER

No intervention

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All patients diagnosed with lung cancer and treated

You may qualify if:

• Patients over 18 years of age diagnosed with non-small cell lung cancer Patients over 18 years of age diagnosed with small cell lung cancer Patients diagnosed with lung cancer and undergoing chemotherapy

You may not qualify if:

• Patients with known hematological malignancies other than lung cancer, patients who were diagnosed with anemia before chemotherapy treatment, who received treatment for this reason, patients who were diagnosed with lung cancer in our clinic but did not continue chemotherapy treatment in our clinic afterwards, patients who are thought to impair data integrity due to missing data will be excluded from the study

Sponsors & Collaborators

• Karadeniz Technical University: lead

Study Sites (1)

Department of Chest Diseases, Division Of Intensive Care Medicine, Faculty of Medicine, Karadeniz Technical University

Trabzon, 61100, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

Transfusion Reaction

Interventions

Blood Transfusion

Condition Hierarchy (Ancestors)

Hematologic Diseases; Hemic and Lymphatic Diseases; Immune System Diseases

Intervention Hierarchy (Ancestors)

Biological Therapy; Therapeutics

Study Officials

• Mehtap Küçük, MD

  Department of Chest Diseases, Division Of Intensive Care Medicine, Faculty of Medicine, Karadeniz Technical University

  STUDY CHAIR

• A. Oguzhan Küçük, MD

  Department of Chest Diseases, Division Of Intensive Care Medicine, Faculty of Medicine, Karadeniz Technical University

  STUDY CHAIR

• Merve Algın, MD

  Department of Chest Diseases, Faculty of Medicine, Karadeniz Technical University

  STUDY CHAIR

• Ayşegul Pehlivanlar, MD

  Department of Chest Diseases, Faculty of Medicine, Karadeniz Technical University

  STUDY CHAIR

• Funda Öztuna, Prof

  Department of Chest Diseases, Faculty of Medicine, Karadeniz Technical University

  STUDY CHAIR

• Olcay Ayçiçek

  Department of Chest Diseases, Faculty of Medicine, Karadeniz Technical University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

OLCAY AYCICEK, MD

CONTACT

05324409349; olcayaycicek@yahoo.com

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant professor

Study Record Dates

• First Submitted: June 13, 2021
• First Posted: October 21, 2022
• Study Start: October 1, 2020
• Primary Completion: November 2, 2022
• Study Completion: November 30, 2022
• Last Updated: October 21, 2022

Record last verified: 2022-04

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)